Determining triglyceride reductions needed for clinical impact in severe hypertriglyceridemia.

Area of Science:

• Cardiology
• Endocrinology
• Public Health

Background:

• Severe hypertriglyceridemia (triglycerides ≥ 500 mg/dL) elevates risks for cardiovascular disease and pancreatitis.
• Optimal triglyceride targets for clinical benefit in this population remain undefined.

Purpose of the Study:

• To evaluate the association between follow-up triglyceride levels and the incidence of clinical events in adults with severe hypertriglyceridemia.

Main Methods:

• Retrospective cohort study using US healthcare claims data (June 2001–September 2010).
• Identified 41,210 adults with severe hypertriglyceridemia, categorizing them by follow-up triglyceride levels (6–24 weeks post-index).
• Adjusted Cox regression models assessed the impact of triglyceride levels on pancreatitis and cardiovascular events.

Main Results:

• Patients achieving follow-up triglyceride levels <200 mg/dL showed significantly lower rates of pancreatitis (IRR, 0.45) and cardiovascular events (IRR, 0.71).
• Clinical benefits were also observed for levels between 200-299 mg/dL and 300-399 mg/dL (P < .001 for trend).

Conclusions:

• The lowest follow-up triglyceride levels demonstrated the most significant reduction in clinical events for patients with severe hypertriglyceridemia.